tbuckley/cabot-search huggingface dataset:
Comparison of Patients with ST-Segment Elevation Myocardial Infarction enrolled in Fibrinolytic Drug Trials with Trial-Eligible and Trial-Ineligible Patients: Findings from the Global Registry of Acute Coronary Events
Authors: PG Steg, JL Lúpez-Sendún, SG Goodman, JM Gore, FA Anderson, D Himbert, J Allegrone, Frans Van de Werf
Journal: Circulation (2004)
Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study
Authors: Andrea Arfè, Lorenza Scotti, Cristina Varas-Lorenzo, Federica Nicotra, Antonella Zambon, Bianca Kollhorst, Tania Schink, Edeltraut Garbe, Ron Herings, Huub Straatman, René Schade, Marco Villa, Silvia Lucchi, Vera Valkhoff, Silvana Romio, Frantz Thiessard, Martijn Schuemie, Antoine Pariente, Miriam Sturkenboom, Giovanni Corrao
Journal: BMJ (2016)

<b>Objectives</b>&nbsp;To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. <b>Design</b>&nbsp;Nested case-control study. <b>Setting</b>&nbsp;Five population based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom). <b>Participants</b>&nbsp;Adult individuals (age ≥18 years) who started NSAID treatment in 2000-10. Overall, 92 163 hospital admissions for heart failure were identified and matched with 8 246 403 controls (matched via risk set sampling according to age, sex, year of cohort entry). <b>Main outcome measure</b>&nbsp;Association between risk of hospital admission for heart failure and use of 27 individual NSAIDs, including 23 traditional NSAIDs and four selective COX 2 inhibitors. Associations were assessed by multivariable conditional logistic regression models. The dose-response relation between NSAID use and heart failure risk was also assessed. <b>Results</b>&nbsp;Current use of any NSAID (use in preceding 14 days) was found to be associated with a 19% increase of risk of hospital admission for heart failure (adjusted odds ratio 1.19; 95% confidence interval 1.17 to 1.22), compared with past use of any NSAIDs (use &gt;183 days in the past). Risk of admission for heart failure increased for seven traditional NSAIDs (diclofenac, ibuprofen, indomethacin, ketorolac, naproxen, nimesulide, and piroxicam) and two COX 2 inhibitors (etoricoxib and rofecoxib). Odds ratios ranged from 1.16 (95% confidence interval 1.07 to 1.27) for naproxen to 1.83 (1.66 to 2.02) for ketorolac. Risk of heart failure doubled for diclofenac, etoricoxib, indomethacin, piroxicam, and rofecoxib used at very high doses (≥2 defined daily dose equivalents), although some confidence intervals were wide. Even medium doses (0.9-1.2 defined daily dose equivalents) of indomethacin and etoricoxib were associated with increased risk. There was no evidence that celecoxib increased the risk of admission for heart failure at commonly used doses. <b>Conclusions</b>&nbsp;The risk of hospital admission for heart failure associated with current use of NSAIDs appears to vary between individual NSAIDs, and this effect is dose dependent. This risk is associated with the use of a large number of individual NSAIDs reported by this study, which could help to inform both clinicians and health regulators.
PTH-221 Malnutrition in patients undergoing colorectal surgery as part of the enhanced recovery programme: Abstract PTH-221 Table 1
Authors: B Rye, JT Jenkins, A Culkin
Journal: Gut (2015)

<h3>Introduction</h3> Colorectal cancer (CRC) is the 4<sup>th</sup>most common cancer in the UK.<sup>1</sup>The prevalence of malnutrition in CRC ranges from 2–48% depending on the definition used and stage of cancer.<sup>2 </sup>Surgery is the primary treatment for CRC but may increase the risk of malnutrition by altering the metabolism of the patient.<sup>3 </sup>Malnutriton before gastrointestinal surgery is associated with worse outcome.<sup>4 </sup>Enhanced Recovery After Surgery (ERAS) aims to reduce the metabolic response to surgery promoting an earlier return to normal physiology.<sup>5</sup>The aim of this study was to examine the perioperative nutritional status of patients with CRC on an ERAS programme. <h3>Method</h3> A prospective observational design was used. A nutritional assessment was completed in clinic before and after surgery. This included weight, height, BMI, percentage weight loss, tricep skinfold thickness, mid-arm muscle circumference, hand grip strength, five times sit to stand test and the malnutrition universal screening tool (MUST). A preoperative micronutrient blood test was taken. Descriptive statistics, paired sample t-test, multiple and linear regression were performed. Ethical approval was obtained. <h3>Results</h3> Twenty-five patients were recruited. Table 1shows the prevalence of malnutrition before and after surgery. Fifty-six percent of patients had vitamin D deficiency or insufficiency and 32% were anaemic preoperatively. Preoperative zinc and selenium levels were normal in all patients. Significant reductions in weight (-3.7 kg, p = 0.001) BMI (-1.3 kg/m², p = 0.001), mid-arm circumference (-1.5 cm, p = 0.001), tricep skinfold thickness (-1.2 mm, p = 0.004) and mid-arm muscle circumference (-1 cm, p-0.001) were found post-operatively. No significant changes in hand grip or sit to stand test were found. Preoperative BMI (p = 0.024), tricep skinfold thickness (p = 0.004) and hand grip strength (p = 0.028) may predict length of hospital stay but limited by sample size. <h3>Conclusion</h3> Patients with CRC awaiting surgery are at risk of malnutrition, reduced functional capacity, vitamin D deficiency and anaemia. This study demonstrates patients on an ERAS programme experienced significant deteriorations in perioperative nutritional status. Preoperative nuritional assessment is able to identify patients at risk of malnutrition and may facilitate initiation of preoperative nutritional support. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Cancer Research UK. Bowel Cancer 2014 [Online] Garth AK, <i>et al.</i>J Hum Nutr Diet 2010;23:393–401 Finnerty CC, <i>et al.</i><i>JPEN</i>2013;37:21–29 Jean-Claude M, <i>et al.</i>Clin Nutr 2012;31:896–902 Rao PKD, Haray PN. <i>Surgery</i>2014;<b>32</b>:185–189
Multifaceted role of hair follicle dermal cells in bioengineered skins
Authors: C.A. Higgins, M.F. Roger, R.P. Hill, A.S. Ali-Khan, J.A. Garlick, A.M. Christiano, C.A.B. Jahoda
Journal: British Journal of Dermatology (2016)

The method of generating bioengineered skin constructs was pioneered several decades ago; nowadays these constructs are used regularly for the treatment of severe burns and nonhealing wounds. Commonly, these constructs are comprised of skin fibroblasts within a collagen scaffold, forming the skin dermis, and stratified keratinocytes overlying this, forming the skin epidermis. In the past decade there has been a surge of interest in bioengineered skins, with researchers seeking alternative cell sources, or scaffolds, from which constructs can be established, and for more biomimetic equivalents with skin appendages.To evaluate whether human hair follicle dermal cells can act as an alternative cell source for engineering the dermal component of engineered skin constructs.We established in vitro skin constructs by incorporating into the collagenous dermal compartment: (i) primary interfollicular dermal fibroblasts, (ii) hair follicle dermal papilla cells or (iii) hair follicle dermal sheath cells. In vivo skins were established by mixing dermal cells and keratinocytes in chambers on top of immunologically compromised mice.All fibroblast subtypes were capable of supporting growth of overlying epithelial cells, both in vitro and in vivo. However, we found hair follicle dermal sheath cells to be superior to fibroblasts in their capacity to influence the establishment of a basal lamina.Human hair follicle dermal cells can be readily interchanged with interfollicular fibroblasts and used as an alternative cell source for establishing the dermal component of engineered skin both in vitro and in vivo.
Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasis
Authors: Chunyang Jiang, Xin Li, Hui Zhao, Huibin Liu
Journal: Molecular Cancer (2016)

Long non-coding RNAs (lncRNAs) play important roles in malignant neoplasia. Indeed, many hallmarks of cancer define that the malignant phenotype of tumor cells are controlled by lncRNAs. Despite a growing number of studies highlighting their importance in cancer, there has been no systematic review of metastasis-associated lncRNAs in various cancer types. Accordingly, we focus on the key metastasis-related lncRNAs and outline their expression status in cancer tissues by reviewing the previous stuides, in order to summarize the nowadays research achivements for lncRNAs related to cancer metastasis. Medline, EMBASE, as well as PubMed databases were applied to study lncRNAs which were tightly associated with tumor invasion and metastasis. Up to now, a substantial number of lncRNAs have been found to have important biological functions. In this review, according to their various features in cancer, lncRNAs were roughly divided into three categories: promoting tumor invasion and metastasis, negative regulation of tumor metastasis and with dual regulatory roles. The present studies may establish the foundation for both further research on the mechanisms of cancer progression and future lncRNA-based clinical applications.
Lenalidomide Consolidation Followed by Maintenance After Autologous Transplantation for Multiple Myeloma Decreases Thymic Output and Terminally Differentiated CD4 and CD8 T Cells but Increases Treg
Authors: Emmanuel Clave, Corinne Douay, Tereza Coman, Marc Busson, Caroline Bompoint, Helene Moins, Maryvonnick Carmagnat, Norbert Claude Gorin, Dominique Charron, Antoine Toubert, Laurent Garderet
Journal: Blood (2012)
Lipocalin 2: An Emerging Player in Iron Homeostasis and Inflammation
Authors: Xia Xiao, Beng San Yeoh, Matam Vijay-Kumar
Journal: Annual Review of Nutrition (2017)

Lipocalin 2 (Lcn2), an innate immune protein, has emerged as a critical iron regulatory protein during physiological and inflammatory conditions. As a bacteriostatic factor, Lcn2 obstructs the siderophore iron-acquiring strategy of bacteria and thus inhibits bacterial growth. As part of host nutritional immunity, Lcn2 facilitates systemic, cellular, and mucosal hypoferremia during inflammation, in addition to stabilizing the siderophore-bound labile iron pool. In this review, we summarize recent advances in understanding the interaction between Lcn2 and iron, and its effects in various inflammatory diseases. Lcn2 exerts mostly a protective role in infectious and inflammatory bowel diseases, whereas both beneficial and detrimental functions have been documented in neurodegenerative diseases, metabolic syndrome, renal disorders, skin disorders, and cancer. Further animal and clinical studies are necessary to unveil the multifaceted roles of Lcn2 in iron dysregulation during inflammation and to explore its therapeutic potential for treating inflammatory diseases.
Highlights in Gastrointestinal (Colorectal) Cancer Treatment
Authors: Kristen K. Ciombor, Richard M. Goldberg
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Clinical Significance of Cytogenetics Evaluated By Conventional Cytogenetic and Interphase Fluorescence in Situ Hybridization Analysis in Newly Diagnosed Multiple Myeloma in Mexico
Authors: Christianne Bourlon, Osvaldo Mutchinick, Cesar Vargas-Serafín, Virginia Santiago-Cano, Renata Rivera, Olga Barrales, Georgina Barrera, Guadalupe Jimenez, Deborah Martínez-Baños
Journal: Blood (2014)
UPDATE On the RISK of SECONDARY LEUKEMIA In GENETIC SUBGROUPS (ELANE, HAX1, WAS, G6PC3, p14) of CONGENITAL NEUTROPENIA In EUROPE
Authors: Cornelia Zeidler, Peter Vandenberghe, Irina Schäfer, Ludwig Hoy, Martin Zimmermann, Manuela Germeshausen, Karl Welte
Journal: Blood (2011)
The effect of age on delay in diagnosis and stage of breast cancer.
Authors: A. H. Partridge, M. E. Hughes, Y. Wong, S. B. Edge, R. L. Theriault, D. W. Blayney, J. C. Niland, E. P. Winer, J. C. Weeks, R. M. Tamimi
Journal: Journal of Clinical Oncology (2010)

1580 Background: Young women with breast cancer are more likely to present with more advanced disease, and are more likely to die of breast cancer than their older counterparts. We sought to examine the relationship between young age (≤ 40 yrs) at diagnosis, likelihood of delay in diagnosis, and stage at presentation. Methods: We examined data from women with newly diagnosed stage 1-4 breast cancer presenting to one of 8 NCCN centers between January 2000 and December 2007. Delay in diagnosis was defined as time from triggering event to breast cancer diagnosis > 60 days. Triggering event was collected via patient report at baseline, and categorized as abnormal screening mammography vs. breast/axillary sign or symptom. Results: Among 22,787 women with breast cancer eligible for analysis, 2,570 were ≤ 40 at diagnosis, with an average age of 35; the average age of women > 40 was 57. Compared to older women, young women were more likely to be: non-white, premenopausal, more educated, employed, not insured through Medicare, diagnosed with advanced stage disease. Young women were more likely to have a delay in diagnosis of > 60 days (36% vs. 26%, p < 0.0001). A symptomatic triggering event was reported by 85.9% of young women (10.0% screen mammo, 4.5% other) compared with 50.2% of older women (46.2% screen mammo, 3.7% other). In a logistic regression model adjusting for race/ethnicity, employment status, education, insurance, NCCN center, and height/weight, young women were more likely to have delay in diagnosis (OR 1.51, 95% CI 1.37-1.65; p < 0.001). However, after additional adjustment for type of triggering event, there was no longer an association (OR = 1.07, 95% CI 0.97-1.18; p = 0.18). Among women with a symptom as the triggering event, there was a 10% increased risk of a delay for young women (OR=1.11, 1.00-1.22; p=0.04). Delay was associated with higher risk of advanced stage at diagnosis in an adjusted analysis (OR = 1.6, 95% CI 1.5-1.7; p < 0.0001). Conclusions: Young women are more likely to present with a local symptom of breast cancer and have a delay in diagnosis, which is associated with more advanced stage. Future research to characterize delays and their impact, and to improve detection and awareness of breast cancer in young women is warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ASCO, University of Michigan Bristol-Myers Squibb BCBS Michigan, NCCN
Gata1 Regulates Erythroid Transcription by Cooperating with Chromatin Remodeling Protein Snf2h
Authors: Jarmila Podskocova, Pavel Burda, Karin Vargova, Juraj Kokavec, Nikola Curik, Jiri Zavadil, Arthur Skoultchi, Tomas Stopka
Journal: Blood (2008)
James Graham Pinney Hutchison
Authors: Tom Hutchison, Anne Hutchison
Journal: BMJ (2016)

James Graham Pinney Hutchison entered the Royal Army Medical Corps and was posted to Trinidad in 1947. As a civilian he embraced pathology and trained at the Royal Victoria Infirmary in Newcastle, before moving to a lecturership in bacteriology at the Western Infirmary Glasgow in 1957. The professor, Sir James Howie, became a mentor and persuaded him to move to Birmingham …
Nearly one in 10 premature babies did not have a temperature check in first hour after birth, UK audit finds
Authors: Susan Mayor
Journal: BMJ (2016)

More than one in four babies born earlier than 32 weeks gestation and whose temperature was recorded within an hour of birth were below the recommended range of 36.5°C to 37.5°C, results from the latest national neonatal audit programme report have shown.1

Nearly one in eight of the 750 000 babies born each year in England, Wales, and Scotland were admitted to a neonatal unit because they were born prematurely, had a low birth weight, or had a medical condition that needed specialist treatment.

The national neonatal audit compared results from neonatal units against professionally agreed standards, with the …
Self-exam is the most common method of breast cancer identification
Authors: A. Rosenberg, L. Burke, P. Vos, D. Liles
Journal: Journal of Clinical Oncology (2007)

1543 Background: Breast cancer survival is improved by early diagnosis. The role of self-exam as an adjunct to screening mammography has been questioned as some studies suggest that self-examinations lead to unnecessary diagnostic procedures without improving survival. Methods: Patients who had been diagnosed with breast cancer and who were attending a university-based cancer clinic were interviewed, using a structured questionnaire, to determine the way in which their breast cancers were first identified. Inference was conducted using exact methods (Clopper-Pearson intervals for proportions and Fisher’s test for odds ratios). Results: Breast cancers were first identified by mammogram in 16% of women, by provider in 9%, by the spouse in 2%. Seventy-five percent (95% CI=61% to 85%) of patients first identified their tumors by self exam. Self-identifiers occurred in all demographic groups. These women included those with all types of insurance: private insurance (68%), Medicare (60%), Medicaid (100%), or no insurance (85%); all levels of education: 77% with college education and 75% with high school; all income levels: for example, among 79% with annual incomes of &lt;$10K and 73% with incomes &gt;$50K; and among both black (91%) and white (66%) women. Of the women who reported both regular mammograms and regular self-examination (N=35), 77% (95% CI=60 to 90%) were self-identifiers. However, cancers found by mammography were more likely to be Stage I than were those identified by self-examination (odds ratio=3.9, 95% CI .9 to 17.5, p=.047). Conclusions: Most breast cancers (75%) were found by self-examination, even among women who had regular mammography. We did not find any demographic factor that predicted mammography as the primary method of tumor identification. These findings suggest that self-examination remains an important method of breast cancer identification. No significant financial relationships to disclose.
Efficacy of chlorhexidine application to umbilical cord on neonatal mortality in Pemba, Tanzania: a community-based randomised controlled trial
Authors: Sunil Sazawal, Usha Dhingra, Said M Ali, Arup Dutta, Saikat Deb, Shaali M Ame, Mkasha H Mkasha, Ashish Yadav, Robert E Black
Journal: The Lancet Global Health (2016)

BackgroundIn low-income countries, including the east African region, a third of neonatal deaths are due to infections. A substantial proportion of these have been attributed to sepsis, which can result from umbilical cord infections. Evidence from Asia suggests that chlorhexidine application to the neonatal umbilical cord reduces mortality, but no data from Africa are available. We aimed to assess the effect of umbilical cord cleansing with 4% chlorhexidine solution on neonatal mortality and omphalitis in rural settings of sub-Saharan Africa.MethodsWe did a community-based randomised controlled trial on Pemba Island, Zanzibar, Tanzania. All eligible babies (aged 1 h to 48 h, without congenital malformations) from hospital-based and community-based deliveries on Pemba Island were enrolled. Participants were randomly assigned to either 4% free chlorhexidine for cord care or to dry cord care using a computer-generated random sequence. For babies allocated to the chlorhexidine group, mothers or caretakers were advised to apply the solution to the cord every day until 3 days after the cord had dropped off. Cord stumps were examined for redness, pus, swelling, and foul odour on day 0, 1, 4, 10, and 28. The primary outcome for this study was mortality until day 28 on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, number NCT01528852.FindingsBetween May 19, 2011, and Aug 31, 2014, 36 911 newborn babies were enrolled into the chlorhexidine (n=18 015) and dry cord care study (n=18 896) groups. 17 468 (96·9%) of 18 015 neonates in the chlorhexidine group were available for complete follow-up (28 days) compared with 18 384 (97·3%) of 18 896 neonates in the dry cord care group. Mortality rate in the chlorhexidine group (10·5 deaths per 1000 livebirths) was not significantly lower than that in the dry cord care group (11·7 per 1000 livebirths; relative risk 0·90, 0·74–1·09; p=0·27).InterpretationOur findings do not support the use of chlorhexidine for reduction of neonatal mortality in this east African setting, which might not justify a change in the WHO policy. To inform global policy, a detailed meta-analysis and pooled analysis needs to be undertaken using data from both African and Asian settings.FundingBill & Melinda Gates Foundation.
EFFICACY OF CHEMOTHERAPY plus CETUXIMAB ACCORDING TO METASTATIC SITE IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: ANALYSIS OF CRYSTAL AND OPUS STUDIES
Authors: Claus-Henning Koehne, Carsten Bokemeyer, Steffen Heeger, Philippe Rougier, Eric Van Cutsem
Journal: Annals of Oncology (2011)
Reply to Mavrogenis et al.
Authors: Jean-Michel Gonzalez, Marc Barthet
Journal: Endoscopy (2016)

We received and paid careful attention to the letter written by Mavrogenis et al. First, we would like to thank them very much for reacting to our paper. We recognize that the approach consisting of endoscopic submucosal dissection (ESD) for esophageal recanalization is elegant and would be a good alternative to the double scope rendezvous technique.